Skin Vaccination Summit 2013

4-6 September, Bell Harbor Conference Centre, Seattle, Washington, USA

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 5th September

SESSION 5:
ADJUVANTS & DELIVERY TECHNOLOGIES FOR VACCINATION INTO SKIN

Moderator: Mark Kendall (University of Queensland, Brisbane, Queensland, Australia)

09.00-09.30
‘Adjuvants for intradermal vaccination’
Steve Reed (IDRI, Seattle, Washington, USA)

09.30-09.50
‘Adjuvanted intradermal immunization with inactivated poliovirus vaccine’
Elizabeth B. Norton and John D. Clements (Tulane University School of Medicine, New Orleans, USA)

09.50-10.10
‘Elucidation of the immunephenotype from electroporation mediated DNA vaccine delivery to the skin’
Kate Broderick, Trevor Smith, Jay McCoy and Niranjan Y. Sardesai (INOVIO Inc., Blue Bell, Pennsylvania, USA)

10.10-10.30
‘Intradermal priming with DNA plasmids containing HIV-1 genes with the Biojector is safe and superior to intramuscular priming’
Eric Sandstrom (Karolinska Institute, Stockholm, Sweden – for HIVIS/TaMoVac Study Group)

10.30-10.50
‘Co-localizing nanopatch-mediated skin damage with adjacent live cells and vaccine enhances systemic immunogenicity’
A. Depelsenaire, F. Pearson, O. Haigh, C. McNeilly, C. Flaim and M. Kendall (University of Queensland, Brisbane, Queensland, Australia)

10.50-11.10
Coffee Break & Posters

SESSION 6:
MICRONEEDLE SYSTEMS I

Moderator: Nathalie Garcon (GSK Biologicals, Rixensart, Belgium)

11.10-11.40
‘Nanopatches: Improving the reach of vaccines with targeted delivery to skin and thermostability’
Mark Kendall (University of Queensland, Brisbane, Queensland, Australia)

11.40-12.10
‘Chemical modification of silicon microneedle arrays with ionizable surface groups for pH-triggered dermal vaccination’
Joke A. Bouwstra, Huixin Yu, Karen Sliedregt, Alexander Kros, Wim Jiskoot and Koen van der Maaden (Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands)

12.10-12.40
‘Simplifying vaccine administration with transdermal MicroCor®’
Bobby Singh (Corium International, Menlo Park, California, USA)

12.40-13.00
‘Developing and scale-up of a coated microneedle patch’
Kristine Hansen, David Wirtanen, Kevin Puckett, Ryan Simmers, Ed Truskoluski and Daniel Dohmeier (3M Drug Delivery Systems, St. Paul, Minnesota, USA)

13.00-14.00
Lunch Break & Posters

SESSION 7:
MICRONEEDLE SYSTEMS II

Moderator: Bobby Singh (Corium International, Menlo Park, California, USA)

14.00-14.30
‘ImmuPatch microneedle systems for addressing unmet needs in immunization programmes’
A. Moore, E. Allen, C. O’Mahony and A. Crean (University College Cork, Cork, Ireland)

14.30-15.00
‘A microneedle patch for influenza vaccine: US policy considerations and cost modeling’
Courtney Jarrahian (PATH, Seattle, Washington, USA)

15.00-15.20
‘Safety and efficacy of influenza vaccine delivered intracutaneously from a microneedle-based device’
Renee L. Herber (FluGen Inc., Madison, Wisconsin, USA)

15.20-15.40
‘Title to be confirmed’
Philippe Laurent (BD Medical Pharmaceutical Systems, Le Point de Claix, France)

15.40-16.00
Tea Break & Posters

SESSION 8:
NOVEL APPLICATIONS VIA THE SKIN

Moderator: John D. Clements (Tulane University School of Medicine, New Orleans, USA)

16.00-16.30
‘Skin immunization of non-human primates with influenza subunit vaccine’
Ioanna Skountzou, Chris Ibegbu, Priya Kalluri, Devin McAllister, E.Stein Esser, Misha Taherbha, Elena Vassilieva, Chris Edens, Joanna Pulit-Penaloza, Surinder P. Kaur, Dimitrios Koutsonanos, Mark R. Prausnitz and Richard Compans (Emory University, Atlanta, Georgia, USA)

16.30-17.00
‘Immunogenicity of plant-made influenza VLP vaccines administered intradermally’
Sonia Trepanier and Nathalie Landry (Medicago, Ste-Foy, Quebec, Canada)

17.00-17.20
‘Depth controlled microinjections for dermal vaccination: A study with polio vaccine in rats’
Koen van der Maaden, Bas Trietsch, Wim Jiskoot and Joke A. Bouwstra (Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands)

17.20-17.40
‘Antibiotic-free plasmid vectors with improved transgene expression after intradermal delivery’
Jim Williams (Nature Technology Corporation, Lincoln, Nebraska, USA)

17.40-18.00
‘Ultrasound-assisted transcutaneous immunization’
Matthias A. Oberli, Diviya Sinha, Gregory L. Szeto, Carmen Gerlach, Ulrich H. Von Andrian, Robert Langer and Daniel Blankschtein (MIT, Cambridge, Massachusetts, USA)

Free Evening for SVS 2013 Delegates

 

SVS 2013 Delegates

Login details will be supplied after you have registered for the event.


SVS 2013 Sponsors

  • Drug Delivery Letters
  • Becton Dickinson
  • Debiotech
  • NanoPass
  • Current Drug Delivery
  • ONdrugDELIVERY
  • Univac
  • 3M
  • West
  • Bioject
  • Nature Gene Therapy
  • Infectious Disease Research Institute
  • Corium
  • Inovio Pharmaceuticals
  • Novartis Vaccines
  • Star Syringe
  • Sanofi Pasteur
  • Path
  • Aldevron
  • DNA Vaccine
  • Zoetis
  • PharmaJet
  • Sanaria

SVS 2013 Downloads

SVS 2013 Leaflet

SVS 2013 Mailing List

Name
E-mail Address
What is 1+4-2?